Cytoplasmic p21 and Cisplatin Sensitivity in Ovarian Cancer
Author Information
Author(s): Xia Xi, Ma Quanfu, Li Xiao, Ji Teng, Chen Pingbo, Xu Hongbin, Li Kezhen, Fang Yong, Weng Danhui, Weng Yanjie, Liao Shujie, Han Zhiqiang, Liu Ronghua, Zhu Tao, Wang Shixuan, Xu Gang, Meng Li, Zhou Jianfeng, Ma Ding
Primary Institution: Tongji Medical College, Huazhong University of Science and Technology
Hypothesis
This study investigates the role of cytoplasmic p21 in cisplatin resistance in ovarian cancer.
Conclusion
Cytoplasmic p21 is a novel biomarker of cisplatin resistance and may represent a potential therapeutic target for ovarian tumors that are resistant to conventional treatment.
Supporting Evidence
- Cytoplasmic p21 was predominantly localized in the resistant cell line C13* compared to the sensitive line OV2008.
- Knockdown of cytoplasmic p21 increased cisplatin-induced apoptosis in C13* cells.
- Immunohistochemical analysis showed that cytoplasmic p21 was negatively correlated with response to cisplatin treatment.
Takeaway
This study found that a protein called p21 in the cytoplasm of ovarian cancer cells can make them resistant to a common cancer drug called cisplatin.
Methodology
The study used RT-PCR, western blot, immunofluorescence, and flow cytometry to analyze p21 expression and its effects on cisplatin-induced apoptosis in ovarian cancer cell lines.
Limitations
The study did not analyze the prognosis and survival rates of patients.
Participant Demographics
Patients diagnosed with ovarian carcinoma who received cisplatin-based chemotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website